Zofran
Classical Hodgkin Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.Phase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 81/ 100
Competitive context
35 Active assets in the Classical Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DACARBAZINE City of Hope Medical Center | Phase 3 | BB |
VINBLASTINE University of Washington | Phase 2 | BB |
Inno-206 Michael Spinner, MD | Phase 3 | BB |
ETOPOSIDE Masonic Cancer Center, University of Minnesota | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 3 | BB |
View all 46 →
Same molecule, other indications
Zofran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →